Royalty Pharma plc (RPRX) Completes $2B Senior Notes Offering, Strengthens Capital for Growth [Yahoo! Finance]
Royalty Pharma plc - Class A Ordinary Shares (RPRX)
US:NASDAQ Investor Relations:
ir.reprosrx.com/investor-relations
Company Research
Source: Yahoo! Finance
Royalty Pharma plc (NASDAQ:RPRX), a leader in biopharma royalties, made major strategic moves in September 2025. The company completed a $2 billion senior notes offering maturing in 2031, 2035, and 2055, enhancing its ability to acquire long-duration royalty assets, fund deals, and strengthen its capital structure. The firm continues to benefit from growing adoption of royalties, with 87% of biopharma executives considering them for capital needs. Since its 2020 IPO, the corporation has tripled headcount, invested in data analytics, and streamlined operations through manager internalization. Q2 2025 portfolio receipts rose 20% year-over-year, and the company targets $4.7 billion in receipts by 2030, with mid-teens shareholder returns and dividend growth. These trends position Royalty Pharma plc (NASDAQ:RPRX) among the best pharmaceutical stocks for long-term growth. Innovation drives its growth, particularly in oncology. Royalty Pharma plc (NASDAQ:RPRX) announced a $2 billion fun
Show less
Read more
Impact Snapshot
Event Time:
RPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPRX alerts
High impacting Royalty Pharma plc - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
RPRX
News
- Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding AgreementGlobeNewswire
- Royalty Pharma plc (RPRX) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Royalty Pharma (NASDAQ:RPRX) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=RPRX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street ZMarketBeat
- Royalty Pharma to Present at Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma to Present at Upcoming Investor ConferencesGlobeNewswire
RPRX
Sec Filings
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- 12/1/25 - Form 144
- RPRX's page on the SEC website